Fellowship · Charlottesville, VA
Sponsored by University of Virginia Medical Center
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
The New England journal of medicine · 2025 · 748 citations · Christopher Kramer
Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.
Journal of the American College of Cardiology · 2025 · 147 citations · Christopher Kramer
Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.
Nature medicine · 2025 · 111 citations · Christopher Kramer
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy.
Journal of the American College of Cardiology · 2023 · 175 citations · Christopher Kramer
2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.
The Journal of thoracic and cardiovascular surgery · 2023 · 125 citations · Christopher Kramer
Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial.
JAMA · 2023 · 150 citations ·
Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity.
Nature genetics · 2021 · 272 citations · Christopher Kramer
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.
Circulation · 2025 · 56 citations · Christopher Kramer